INmune Bio Terminates $75M At-the-Market Sales Agreement With RBC Capital Markets And BTIG, Effective December 19, 2025; Prior To Termination, The Co Issued And Sold 1,353,469 Shares Of Common Stock Under The Sales Agreement, Raising Net Proceeds Of ~$10.5M

As previously disclosed, on August 9, 2024,  INmune Bio Inc. (the "Company") entered into an Amended and Restated At-The-Market Sales Agreement (the "Sales Agreement") with RBC Capital Markets, LLC ("RBC") and BTIG, LLC ("BTIG"), pursuant to which the Company could offer and sell shares of its common stock, par value $0.001 per share ("Common Stock"), having an aggregate offering price of up to $75,000,000, from time to time through RBC and BTIG in "at-the-market offerings" as defined in Rule 415 of the Securities Act of 1933, as amended.

 

On December 5, 2025 and December 9, 2025, pursuant to and in accordance with Section 12(b) of the Sales Agreement, the Company notified RBC and BTIG, respectively, that the Company is terminating the Sales Agreement, effective December 19, 2025. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement. Prior to termination, the Company issued and sold 1,353,469 shares of Common Stock under the Sales Agreement, raising net proceeds of approximately $10.5 million.